arrow
R

Robert D. Little

Alfred Health
H指数:11
被引数:305

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Trends in Length of Stay, Steroid Use and Colectomy Rates in Patients Admitted with Acute Severe Ulcerative Colitis: The Impact of Accelerated and Intensified Infliximab Dosing

急性重度溃疡性结肠炎住院患者的住院时长、糖皮质激素使用及结肠切除术率趋势:加速和强化英夫利昔单抗给药的影响

2026-01-030
PRE
Randomised controlled trial of continued intravenous versus switching to subcutaneous infliximab in inflammatory bowel disease: the Subcutaneous Infliximab Switch Study (SISS).

随机对照试验:炎症性肠病患者持续静脉注射与转为皮下注射英夫利昔单抗的比较——皮下注射英夫利昔单抗转换研究(SISS)

2026-01-010
PRE
Impaired health-related quality of life is associated with alterations in gut microbiota signatures in patients with Inflammatory Bowel Disease: baseline data from the Australian IBD Microbiome study
2025-01-220
PRE
Association of gut microbiota changes and disease activity in patients with Crohn's disease and ulcerative colitis: baseline data from the Australian IBD Microbiome study
2025-01-220
PRE
Microbial signatures associated with Inflammatory Bowel Disease in Australia: baseline data from the Australian IBD Microbiome study
2025-01-220
PRE
Dietary Patterns and Fibre Intake Are Associated with Disease Activity in Australian Adults with Inflammatory Bowel Disease: An Exploratory Dietary Pattern Analysis
2024-12-170
OAAI
Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease-Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics

炎症性肠病中皮下注射英夫利昔单抗的治疗药物监测-了解皮下生物制剂新时代的药代动力学和暴露反应关系

2022-10-1922
OAAI